Research programme: antisense oligonucleotide therapeutics targeting fibrotic and inflammatory diseases - Secarna Pharmaceuticals
Latest Information Update: 21 Dec 2023
At a glance
- Originator Secarna Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Antisense oligonucleotides
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Inflammation
Most Recent Events
- 21 Dec 2023 Preclinical development in fibrosis is ongoing in Germany (Parenteral)
- 21 Dec 2023 Preclinical trials in Inflammation in Germany (Parenteral) before December 2023 (Secarna Pharmaceuticals pipeline, December 2023)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Fibrosis in Germany (Parenteral)